Table 3 Summary of the sociodemographic characteristics and treatments administered to patients with Behçet’s disease in the RISE (U.S.) registry and studies from endemic regions
Characteristics | Patients with BD in U.S. (RISE) (N = 1323) | Patients with BD in Egypt (ECR) [11] (N = 1526) | Patients with BD in Turkey [12] (N = 682) | Patients with BD in Iran [7] (N = 163) | Patients with BD in Japan [13] (N = 135) | |
|---|---|---|---|---|---|---|
Sociodemographic | Age, mean (SD) | 48.7 (16.3) | 35.7 (9.84) | 33.0 (9.9) | NR | NR |
Female, N (%) | 1049 (79.3) | 424 (27.8) | 113 (16.6) | 63 (38.7) | 78 (57.8) | |
Medications | Colchicine, N (%) | 728 (55.0) | 611 (82.7) | 599 (87.8) | 108 (66.3) | 90 (66.7) |
Dapsone, N (%) | 62 (4.7) | NR | NR | NR | 0 (0.0) | |
Glucocorticoids, N (%) | 895 (67.6) | 947 (90.2) | 384 (56.3) | 110 (67.5) | 78 (57.8) | |
cDMARDs, N (%) | 1 (0.70) | |||||
Azathioprine, N (%) | 418 (31.6) | 474 (26.7) | 347 (50.8) | 48 (29.4) | 17 (12.6) | |
Methotrexate, N (%) | 288 (21.8) | 67 (7.2) | 14 (2.1) | 51 (31.3) | 9 (6.7) | |
Hydroxychloroquine, N (%) | 117 (8.8) | NR | NR | NR | NR | |
Sulfasalazine, N (%) | 53 (4.0) | NR | 51 (7.5) | 3 (5.4) | 31 (23.0) | |
Mycophenolate, N (%) | 31 (2.3) | NR | NR | 0 (0.0) | 0 (0.0) | |
Leflunomide | 26 (1.9) | NR | NR | NR | NR | |
Cyclosporine, N (%) | 23 (1.5) | 282 (26.7) | 93 (13.6) | 13 (8.0) | 14 (10.4) | |
Cyclophosphamide, N (%) | < 10 | 208 (20.1) | 39 (5.7) | 39 (23.9) | 0 (0.0) | |
Minocycline, N (%) | < 10 | NR | NR | NR | NR | |
Tacrolimus, N (%) | 11 (0.83) | NR | NR | NR | NR | |
Biologics-TNFi, N (%) | 389 (29.4) | 83 (8.3) | NR | 1 (0.60) | NR | |
Infliximab, N (%) | 192 (14.5) | NR | 4 (0.6) | NR | NR | |
Adalimumab, N (%) | 187 (14.1) | NR | NR | NR | 10 (7.4) | |
Etanercept, N (%) | 92 (6.9) | NR | NR | NR | 1 (0.70) | |
Golimumab, N (%) | 20 (1.5) | NR | NR | NR | 0 (0.0) | |
Certolizumab, N (%) | 30 (2.3) | NR | NR | NR | NR | |
Biologics-non-TNFia, N (%) | 59 (4.5) | NR | NR | NR | NR | |
tsDMARDs | 53 (4.0) | NR | NR | NR | NR | |